These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 22009816)

  • 1. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy.
    Mohammadi M; Akhondzadeh S
    Acta Med Iran; 2011; 49(8):487-98. PubMed ID: 22009816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attention deficit hyperactivity disorder in adults.
    Rösler M; Casas M; Konofal E; Buitelaar J
    World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-deficit/hyperactivity disorder.
    Shaywitz BA; Fletcher JM; Shaywitz SE
    Adv Pediatr; 1997; 44():331-67. PubMed ID: 9265975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian motor activity affected by stimulant medication in children with attention-deficit/hyperactivity disorder.
    Ironside S; Davidson F; Corkum P
    J Sleep Res; 2010 Dec; 19(4):546-51. PubMed ID: 20629940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor skills of children newly diagnosed with Attention Deficit Hyperactivity Disorder prior to and following treatment with stimulant medication.
    Brossard-Racine M; Shevell M; Snider L; Bélanger SA; Majnemer A
    Res Dev Disabil; 2012; 33(6):2080-7. PubMed ID: 22796639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
    Prince JB
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention-deficit hyperactivity disorder.
    Calis KA; Grothe DR; Elia J
    Clin Pharm; 1990 Aug; 9(8):632-42. PubMed ID: 1974836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.
    Gerwe M; Stollhoff K; Mossakowski J; Kuehle HJ; Goertz U; Schaefer C; Bogdanow M; Heger S
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):175-86. PubMed ID: 21432582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of adult ADHD.
    Dodson WW
    J Clin Psychol; 2005 May; 61(5):589-606. PubMed ID: 15723384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing ADHD therapy with sustained-release methylphenidate.
    Lawrence JD; Lawrence DB; Carson DS
    Am Fam Physician; 1997 Apr; 55(5):1705-9, 1711-2. PubMed ID: 9105199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
    Bricard C; Boidein F
    Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.